Chronic Lymphocytic Leukemia (CLL) — Deal Benchmarks & Valuation
Market Analysis
Chronic Lymphocytic Leukemia (CLL) is one of the most actively transacted indications in oncology licensing. Phase 2 deals for chronic lymphocytic leukemia (cll) carry a median total deal value of $1.4B, with upfront payments ranging from $122M to $311M. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones.
Milestone structures for chronic lymphocytic leukemia (cll) deals allocate $294M to development milestones, $470M to regulatory milestones, and $412M to commercial milestones. Royalty rates range from 11.2% to 18.4% at the base tier, with tiered escalation reaching 15.2%-22.4% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for chronic lymphocytic leukemia (cll) licensing?
What royalty rates are standard for chronic lymphocytic leukemia (cll) deals?
How are chronic lymphocytic leukemia (cll) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.